VIP Is Being Studied in COVID-19 Trial
One thing that COVID-19 has in common with CIRS patients that we see at Rezilir Health is the major problems are caused by an overactive immune response, often known as the “cytokine storm.”
So it is not surprising that the FDA announced on March 29th that NeuroRx had received approval for an Investigational New Drug study to study IV Vasoactive Intestinal Peptide in COVID-19 patients on a ventilator. The VIP that they are studying is Aviptadil which is a patented synthetic form of Vasoactive Intestinal Polypeptide that has previously shown promise in treating ARDS (Big Pharma not Compounded).
As many of Rezilir patients know VIP, has been extraordinarily helpful to limit and to prevent the overactive immune and inflammatory response that happens in CIRS from Water Damaged Buildings. The biological analogies are quite promising, although getting the formal evidence is critical. Evidence is a must!
While no formal outcomes have been reported in the last 10 days, there are some informal results from the ICU that sound quite promising. More to come!
Have a continued joyous Passover and Easter Weekend
Dr. Tanio
